HUE048922T2 - Immunglobulin vázrégiók, amelyek intracelluláris környezetben fokozott stabilitást mutatnak, továbbá eljárások azonosításukra - Google Patents

Immunglobulin vázrégiók, amelyek intracelluláris környezetben fokozott stabilitást mutatnak, továbbá eljárások azonosításukra

Info

Publication number
HUE048922T2
HUE048922T2 HUE15160739A HUE15160739A HUE048922T2 HU E048922 T2 HUE048922 T2 HU E048922T2 HU E15160739 A HUE15160739 A HU E15160739A HU E15160739 A HUE15160739 A HU E15160739A HU E048922 T2 HUE048922 T2 HU E048922T2
Authority
HU
Hungary
Prior art keywords
methods
enhanced stability
intracellular environment
demonstrate enhanced
immunoglobulin frameworks
Prior art date
Application number
HUE15160739A
Other languages
English (en)
Hungarian (hu)
Inventor
Kathrin Tissot
Stefan Ewert
Der Maur Adrian Auf
Alcide Barberis
Dominik Escher
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HUE048922T2 publication Critical patent/HUE048922T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/80—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/80—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
    • C07K2317/82—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies functional in the cytoplasm, the inner aspect of the cell membrane, the nucleus or the mitochondria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
HUE15160739A 2002-05-22 2003-05-21 Immunglobulin vázrégiók, amelyek intracelluláris környezetben fokozott stabilitást mutatnak, továbbá eljárások azonosításukra HUE048922T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38264902P 2002-05-22 2002-05-22
US43825603P 2003-01-03 2003-01-03

Publications (1)

Publication Number Publication Date
HUE048922T2 true HUE048922T2 (hu) 2020-09-28

Family

ID=29553590

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE15160739A HUE048922T2 (hu) 2002-05-22 2003-05-21 Immunglobulin vázrégiók, amelyek intracelluláris környezetben fokozott stabilitást mutatnak, továbbá eljárások azonosításukra

Country Status (14)

Country Link
US (5) US8853362B2 (https=)
EP (5) EP3656787A1 (https=)
JP (10) JP2006508638A (https=)
CN (4) CN103739706B (https=)
AU (2) AU2003238370B2 (https=)
CA (2) CA2483285C (https=)
CY (1) CY1114225T1 (https=)
DK (2) DK1506236T3 (https=)
ES (3) ES2656427T3 (https=)
HU (1) HUE048922T2 (https=)
NZ (1) NZ536412A (https=)
PT (2) PT2332989E (https=)
SI (2) SI2332989T1 (https=)
WO (1) WO2003097697A2 (https=)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0226727D0 (en) * 2002-11-15 2002-12-24 Medical Res Council Intrabodies
EP2336323A3 (en) * 2005-03-25 2012-05-23 National Research Council Of Canada Method for isolation of soluble polypeptides
AU2016204739C1 (en) * 2005-06-07 2017-10-19 Esbatech, An Alcon Biomedical Research Unit Llc Stable and soluble antibodies inhibiting TNFalpha
NZ563580A (en) 2005-06-07 2010-09-30 Esbatech An Alcon Biomedical R Stable and soluble antibodies inhibiting TNFaplha
AU2013207650B2 (en) * 2005-06-07 2016-04-21 Esbatech, An Alcon Biomedical Research Unit Llc Stable and soluble antibodies inhibiting TNFalpha
AU2011265593B2 (en) * 2005-06-07 2013-08-15 Esbatech, An Alcon Biomedical Research Unit Llc Stable and soluble antibodies inhibiting TNFalpha
ES2547248T3 (es) 2006-04-28 2015-10-02 Delenex Therapeutics Ag Anticuerpos que se unen al dominio extracelular del receptor Tirosina cinasa ALK
JP2009542232A (ja) 2006-07-10 2009-12-03 エスバテック・アーゲー 上皮および／または内皮層を通過するｓｃＦｖ抗体
IN2009DN05758A (https=) * 2007-03-12 2015-07-24 Esbatech Ag
WO2008131575A2 (en) * 2007-04-27 2008-11-06 Esbatech Ag Anti-alk antibodies suitable for treating metastatic cancers or tumors
KR101530723B1 (ko) 2007-06-25 2015-06-22 에스바테크 - 어 노바티스 컴파니 엘엘씨 단일 쇄 항체의 서열에 기초한 공학처리 및 최적화
US20090074780A1 (en) * 2007-06-25 2009-03-19 David Urech Methods of modifying antibodies, and modified antibodies with improved functional properties
EP2197914A1 (en) 2007-09-13 2010-06-23 Delenex Therapeutics AG HUMANIZED ANTIBODIES AGAINST THE ß-AMYLOYD PEPTIDE
AU2013202997B2 (en) * 2008-06-25 2015-01-22 Novartis Ag STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFalpha
AU2015201794B2 (en) * 2008-06-25 2017-01-19 Novartis Ag STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFa
LT3216803T (lt) * 2008-06-25 2020-06-10 Novartis Ag Stabilūs ir tirpūs antikūnai, slopinantys vegf
PL3628686T3 (pl) 2008-06-25 2022-02-28 Novartis Ag Humanizowanie przeciwciał króliczych z zastosowaniem uniwersalnego zrębu przeciwciała
MX345039B (es) * 2008-06-25 2017-01-16 Esbatech Alcon Biomed Res Unit Anticuerpos estables y solubles que inhiben el tnfa.
AU2016273957C1 (en) * 2008-06-25 2019-04-18 Novartis Ag STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFa
PT2752428T (pt) * 2008-06-25 2020-02-14 Novartis Ag Humanização de anticorpos de coelho com utilização de um framework de anticorpos universal
PL3241843T3 (pl) 2008-06-25 2021-12-27 Novartis Ag Optymalizacja rozpuszczalności cząsteczek immunowiążących
CN104004094B (zh) * 2008-06-25 2017-09-22 艾斯巴技术-诺华有限责任公司 使用通用抗体构架进行的兔抗体的人源化
WO2010006454A2 (en) 2008-06-30 2010-01-21 Esbatech, An Alcon Biomedical Research Unit Llc Functionalized polypeptides
MX2011000009A (es) 2008-07-10 2011-08-15 Esbatech Alcon Biomed Res Unit Metodos y composiciones para la administracion mejorada de macromoleculas.
EP3181583A1 (en) 2009-02-24 2017-06-21 ESBATech, an Alcon Biomedical Research Unit LLC Methods for identifying immunobinders of antigens
SG2014014864A (en) * 2009-02-24 2014-09-26 Esbatech Alcon Biomed Res Unit Methods for identifying immunobinders of cell-surface antigens
US8399624B1 (en) 2009-06-25 2013-03-19 Esbatech, An Alcon Biomedical Research Unit Llc Acceptor framework for CDR grafting
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
AR083495A1 (es) 2010-10-22 2013-02-27 Esbatech Alcon Biomed Res Unit Anticuerpos estables y solubles
EP2476754A1 (en) * 2011-01-14 2012-07-18 Bundesrepublik Deutschland, Letztvertreten Durch Den Präsidenten Des Paul-Ehrlich-Instituts Methods for the identification and repair of amino acid residues destabilizing single-chain variable fragments (scFv)
CN103890246A (zh) 2011-08-18 2014-06-25 亲和生物科学公司 可溶性多肽
MX2014004521A (es) 2011-10-20 2014-05-28 Esbatech A Novartis Co Llc Anticuerpo estable de union a antigenos multiples.
EP3165535B1 (en) * 2012-08-22 2019-05-15 Mogam Biotechnology Research Institute Screening and engineering method of super-stable immunoglobulin variable domains and their uses
CA2888583C (en) 2012-11-05 2022-03-29 Delenex Therapeutics Ag Binding members to il-1 beta
WO2014095808A1 (en) 2012-12-17 2014-06-26 Delenex Therapeutics Ag Antibodies against il-1 beta
HK1217960A1 (zh) * 2013-02-15 2017-01-27 Esbatech - A Novartis Company Llc 用於cdr移植的接受体框架
JP2016506752A (ja) * 2013-02-20 2016-03-07 エスバテック − ア ノバルティスカンパニー エルエルシー Ｃｄｒグラフトのためのアクセプターフレームワーク
HRP20251426T1 (hr) 2013-05-06 2026-01-02 Scholar Rock, Inc. Sastavi i postupci za modulaciju faktora rasta
US9737592B1 (en) 2014-02-14 2017-08-22 David Gordon Bermudes Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment
IL313511A (en) 2014-11-12 2024-08-01 Seagen Inc Compounds acting on glycans and methods of using them
US9879087B2 (en) 2014-11-12 2018-01-30 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
IL299203A (en) 2015-10-13 2023-02-01 Eureka Therapeutics Inc ׂ A Delaware Corp Antibody factors specific for human differentiation group 19 and their uses
EP3842450A1 (en) 2015-10-23 2021-06-30 Eureka Therapeutics, Inc. Antibody/t-cell receptor chimeric constructs and uses thereof
EP3373969A4 (en) 2015-11-12 2019-08-14 Siamab Therapeutics, Inc. GLYCANINTERAGING COMPOUNDS AND METHOD OF USE
KR20190003938A (ko) 2016-02-25 2019-01-10 셀 메디카 스위처란트 아게 면역치료를 위한 변형된 세포
IL265484B2 (en) * 2016-09-21 2026-01-01 Aptevo Res & Development Llc CD123 binding proteins, related methods and compositions
EP3541847A4 (en) 2016-11-17 2020-07-08 Seattle Genetics, Inc. COMPOUNDS INTERACTING WITH GLYCANE AND METHODS OF USE
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
KR102653141B1 (ko) 2017-03-03 2024-04-01 씨젠 인크. 글리칸-상호작용 화합물 및 사용 방법
CN112218621A (zh) * 2018-04-10 2021-01-12 西北大学 包含基于靶向亲和域的膜蛋白的胞外囊泡
WO2020069349A1 (en) * 2018-09-27 2020-04-02 Colorado State University Research Foundation Scfv's for live cell imaging and other uses
US12285437B2 (en) 2019-10-30 2025-04-29 The Research Foundation For The State University Of New York Reversing the undesirable pH-profile of doxorubicin via activation of a disubstituted maleamic acid prodrug at tumor acidity
PH12023550015A1 (en) 2020-07-16 2024-03-11 Novartis Ag Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules
CA3172265A1 (en) 2021-03-10 2022-09-15 Dimitri BIELI Antibodies against tdp-43 and methods of using the same
WO2023139292A1 (en) 2022-01-24 2023-07-27 Cambridge Enterprise Limited Tau therapy

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US5817311A (en) * 1993-03-05 1998-10-06 Universite Catholique De Louvain Methods of inhibiting T-cell medicated immune responses with LO-CD2a-specific antibodies
DE4425115A1 (de) 1994-07-15 1996-01-18 Boehringer Mannheim Gmbh Verfahren zur Modifizierung der Stabilität von Antikörpern
AU725609C (en) 1995-08-18 2002-01-03 Morphosys Ag Protein/(poly)peptide libraries
US6696248B1 (en) * 1995-08-18 2004-02-24 Morphosys Ag Protein/(poly)peptide libraries
US6262238B1 (en) 1997-01-14 2001-07-17 Roche Diagnostic, Gmbh Process for modifying the stability of antibodies
AU3587599A (en) 1997-11-28 1999-06-16 Invitrogen Corporation Single chain monoclonal antibody fusion reagents that regulate transcript ion in vivo
GB2344886B (en) 1999-03-10 2000-11-01 Medical Res Council Selection of intracellular immunoglobulins
EP2392596A3 (en) 1999-12-28 2013-11-27 ESBATech, an Alcon Biomedical Research Unit LLC Intrabodies with defined framework that is stable in a reducing environment and applications thereof
GB0008419D0 (en) 2000-04-05 2000-05-24 Bioinvent Int Ab A method for invitro molecular evolution of antibody function
EP1156062A1 (en) 2000-05-12 2001-11-21 GPC Biotech AG Immunomodulatory human MHC class II antigen-binding peptides/proteins
US6410271B1 (en) 2000-06-23 2002-06-25 Genetastix Corporation Generation of highly diverse library of expression vectors via homologous recombination in yeast
DE10039191C1 (de) 2000-08-10 2002-01-17 Infineon Technologies Ag Hochfrequenz-Eingangsstufe

Also Published As

Publication number Publication date
WO2003097697A2 (en) 2003-11-27
EP2332989B1 (en) 2015-04-01
JP2019058191A (ja) 2019-04-18
JP2020171286A (ja) 2020-10-22
JP2017201990A (ja) 2017-11-16
DK2332989T3 (en) 2015-05-11
JP2012228272A (ja) 2012-11-22
EP3656787A1 (en) 2020-05-27
CN102093477A (zh) 2011-06-15
HK1217712A1 (en) 2017-01-20
JP2015227372A (ja) 2015-12-17
DK1506236T3 (da) 2013-03-04
CN102093477B (zh) 2014-02-26
CY1114225T1 (el) 2016-08-31
CA2867542A1 (en) 2003-11-27
JP6918033B2 (ja) 2021-08-11
EP2314622A1 (en) 2011-04-27
SI2332989T1 (sl) 2015-06-30
AU2010202634B2 (en) 2012-08-23
SI2947095T1 (sl) 2020-04-30
US9518108B2 (en) 2016-12-13
US10570190B2 (en) 2020-02-25
WO2003097697A3 (en) 2004-12-09
CN103739706A (zh) 2014-04-23
PT2332989E (pt) 2015-08-05
US20150057191A1 (en) 2015-02-26
CN1662556B (zh) 2013-05-01
CN103739706B (zh) 2015-11-18
HK1152320A1 (en) 2012-02-24
US10125186B2 (en) 2018-11-13
JP2010187678A (ja) 2010-09-02
ES2537104T3 (es) 2015-06-02
JP2013078343A (ja) 2013-05-02
EP2332989A1 (en) 2011-06-15
US8853362B2 (en) 2014-10-07
CA2867542C (en) 2020-04-14
JP2006508638A (ja) 2006-03-16
JP6100544B2 (ja) 2017-03-22
AU2003238370B2 (en) 2010-04-29
NZ536412A (en) 2008-10-31
CA2483285A1 (en) 2003-11-27
JP2013256533A (ja) 2013-12-26
JP6075836B2 (ja) 2017-02-08
EP1506236B1 (en) 2013-01-23
ES2399617T3 (es) 2013-04-02
AU2010202634A1 (en) 2010-07-15
CN1662556A (zh) 2005-08-31
EP1506236A2 (en) 2005-02-16
JP2015214583A (ja) 2015-12-03
US20170107272A1 (en) 2017-04-20
EP2947095A1 (en) 2015-11-25
ES2656427T3 (es) 2018-02-27
CA2483285C (en) 2015-01-27
HK1071378A1 (en) 2005-07-15
AU2003238370A1 (en) 2003-12-02
CN105175535A (zh) 2015-12-23
US20190119361A1 (en) 2019-04-25
US20060035320A1 (en) 2006-02-16
US20200165322A1 (en) 2020-05-28
JP6261136B2 (ja) 2018-01-17
EP2947095B1 (en) 2019-10-02
PT1506236E (pt) 2013-03-27
EP2314622B1 (en) 2017-10-18

Similar Documents

Publication Publication Date Title
SI2947095T1 (sl) Imunoglobulinski bralni okvirji, ki kažejo izboljšano stabilnost v znotrajceličnem okolju, in postopki za njihovo identifikacijo
TWI370816B (en) 6-alkyl or alkenyl-4-aminopicolinates and their use as herbicides
PL375691A1 (en) Imidazolopyridines and methods of making and using the same
AU2003282478A8 (en) Discount-instrument methods and systems
AU2003267279A8 (en) Systems and methods for transformable suits
PL381765A1 (pl) Konstrukty wiążące i sposoby ich zastosowania
GB0619264D0 (en) Methods and lens
EP1551447A4 (en) ANTI-ADDL ANTIBODIES AND USES THEREOF
EP1539941A4 (en) ADZYMES AND THEIR USES
ZA200603882B (en) Substituted benzimidazole-, benztriazole-, and benzimidazolone-O-glucosides
IL175491A0 (en) Substituted benzimidazole-, benztriazole-, and benzimidazolone-o-glucosides
EP1550923A4 (en) THREE-DIMENSIONAL DISPLAY AND METHOD FOR THREE-DIMENSIONAL DISPLAY
EG24579A (en) Herbicide composition and weed-controlling method using the same
AU2003265562A8 (en) Computer-aided education systems and methods
GB0202059D0 (en) Chemical compositions and methods
AU2003296369A8 (en) Imminoamines and preparation thereof
SI1551805T1 (sl) Substituirani gama-fenil-delta-laktami in njihova uporaba
GB2408530B (en) Well completion systems and methods
IL172510A0 (en) Antibodies and uses thereof
AU2002346446A1 (en) Methods and compositions in checkpoint signaling
AU2003297612A8 (en) 2-substituted-3-propenamide derivatives and methods of using the same
IL166063A0 (en) Antibodies and uses thereof
AU2003231827A8 (en) Pseudo-tissues and uses thereof
GB0318546D0 (en) Quinoxalinones and their use
SI1506236T1 (sl) Imunoglobulinski bralni okvirji, ki kažejo izboljšano stabilnost v intraceličnem okolju in postopki za njihovo identifikacijo